Protocol Ledger

NCT05392764 · Phase III · RECRUITING

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Interventional Phase III clinical trial protocol NCT05392764 sponsored by Juntendo University in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-10 Enrollment: 444 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05392764
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)444 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05392764
Protocol FieldVerified Registry Value
NCT IdentifierNCT05392764
Consolidated Lead SponsorJuntendo University
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment444 participants (ESTIMATED)
Registered Start Date2022-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05392764
Hospital Research SiteLocationSite Profile
Nagoya University HospitalNagoya, JapanOpen Hospital Dossier ->
Kurume University HospitalKurume, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI